This trial is evaluating whether MINIject™ Implant will improve 2 primary outcomes in patients with Glaucoma. Measurement will happen over the course of 24 months.
This trial requires 975 total participants across 1 different treatment group
This trial involves a single treatment. MINIject™ Implant is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"A wide variety of medical and environmental factors are involved in the development of glaucoma. The high prevalence of open angle glaucoma is due to the increased resistance of the scleral outflow facility, as caused by a chronic elevation in intraocular pressure. Other factors seem to be the main reason for the increased risk of angle closure and its complications." - Anonymous Online Contributor
"There is considerable variability in the ability to prevent the loss of visual acuity from glaucoma. Further research is needed to develop clinical methods to identify which individuals are likely to have good vision at a reasonable risk." - Anonymous Online Contributor
"Recent findings provides evidence that glaucoma is an age-related chronic degenerative optic neuropathy characterized by a slow or gradual progression of visual field loss. The term glaucoma is a misnomer as it is a disease that is not exclusive to the eye, but also encompasses many eye and inner ear symptoms." - Anonymous Online Contributor
"Glaucoma can produce a variety of signs and symptoms such as visual field loss. Many tests can demonstrate if a damage is present or not. Some signs in those affected by glaucoma can be the same as the symptoms. These can include sudden vision loss, pain in the eye, tearing, a red eye, light sensitivity etc.\n" - Anonymous Online Contributor
"The American Academy of Otolaryngology-Head and Neck Surgery estimates that 1 million Americans will be diagnosed with glaucoma a year by 2025, an increase of almost 60% since 2010." - Anonymous Online Contributor
"A variety of glaucoma surgeries can be performed, which may restore vision or may be a palliative measure only. Glaucoma medication is necessary for symptomatic care of patients with glaucoma." - Anonymous Online Contributor
"The current study has found a statistically significant difference in IOP values when miniject™ implant was used (P= 0.001), but the IOP values did not fall significantly in comparison to the controls (P=0.3). In our study, there was no statistically significant difference in the number of antiglaucoma medications between the groups. Results from a recent paper show that miniject™ implant can be helpful in the treatment of glaucoma." - Anonymous Online Contributor
"This article describes how to categorize the risk factors affecting glaucoma by the underlying cause. The various causes of glaucoma are often concurrent. For example, the prevalence of glaucoma is higher in people with refractive error, ocular hypertension, and diabetes, but the underlying mechanism(s) are multifactorial. Other causes include exposure to neurotoxins and UV radiation, as well as genetic factors that predispose to a particular form of glaucoma." - Anonymous Online Contributor
"Mini-injection injection can be used to treat open angle glaucoma without altering medication compliance or requiring a change of injection site (i.e. subconjunctival glaucoma). Additional options include IOP reduction with topical medications, filtering surgery, and trabeculectomy. Mini-injection may be useful with certain medications that may cause toxicity or contraindication to regular application (e.g. beta blockers, sympathomimetics). There is currently insufficient evidence to support the use of multiple minipumps to achieve comparable IOP lowering efficacy or decrease patient morbidity." - Anonymous Online Contributor
"There are many different research areas and there are a few which do appear, along with many others which do not, to have potential impacts over the short to long term. Some of these areas have been studied a great deal and are well-received or receive a lot of attention. Others are more recently being looked at - there is much more research being done and the possible benefits are as yet unclear. Research into different medications has been shown to have some benefits and has led to a number of compounds. There is considerable information about the adverse and long-term effects of conventional glaucoma medication. There has certainly been an increase in knowledge regarding glaucoma over the last few years and one may expect further advances over time." - Anonymous Online Contributor
"Glaucoma is a serious condition. The damage that the disease causes is irreversible and it is important that patients are aware of the severity of their glaucoma when they are first seen for diagnosis. Many people with severe glaucoma will be disabled or lost sight by the time of diagnosis." - Anonymous Online Contributor
"It may be reasonable, particularly for elderly patients who did not have cataracts at the time of the SLT, to use the Miniject™ Implant without lens accommodation. This approach is also a safe way of avoiding corneal damage during the surgery." - Anonymous Online Contributor